This study found that a cell therapy product, RCS-01, was well tolerated in aged skin and led to significant increases in gene expression related to extracellular matrix homeostasis, although the small cohort size limited further efficacy analysis.
January 2024 in “American journal of clinical dermatology” This study reports that ritlecitinib, when used for up to 24 months in patients aged 12 and older with alopecia areata, has an acceptable safety profile, with a similar proportion of adverse events in both ritlecitinib and placebo groups in the placebo-controlled cohort.
April 2024 in “Dermatology reports” This systematic review concluded that dutasteride was more effective than finasteride in increasing hair count for treating androgenetic alopecia in both males and females, with comparable side effects.
6 citations
,
September 2019 in “Skin pharmacology and physiology” This study found that RCS-01 cell therapy for aged skin was well tolerated and associated with increased gene expression related to extracellular matrix homeostasis, suggesting potential skin improvement.
6 citations
,
February 2023 in “Journal of the American Academy of Dermatology” This article addresses the pathogenesis of alopecia areata and discusses the emerging role of oral and topical JAK inhibitors in its treatment, but reports no new clinical findings.